Hubei Biocause Pharmaceutical (000627) - Total Liabilities
Based on the latest financial reports, Hubei Biocause Pharmaceutical (000627) has total liabilities worth CN¥249.15 Billion CNY (≈ $36.46 Billion USD) as of September 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 000627 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Hubei Biocause Pharmaceutical - Total Liabilities Trend (2000–2023)
This chart illustrates how Hubei Biocause Pharmaceutical's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see how large is Hubei Biocause Pharmaceutical's balance sheet.
Hubei Biocause Pharmaceutical Competitors by Total Liabilities
The table below lists competitors of Hubei Biocause Pharmaceutical ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Avanti Feeds Limited
NSE:AVANTIFEED
|
India | Rs8.31 Billion |
|
Tennant Company
NYSE:TNC
|
USA | $735.60 Million |
|
Chengdu Gas Group Co Ltd
SHG:603053
|
China | CN¥3.27 Billion |
|
Metals X Ltd
AU:MLX
|
Australia | AU$76.26 Million |
|
HNA Technology Co Ltd A
SHG:600751
|
China | CN¥2.30 Billion |
|
Suburban Propane Partners LP
NYSE:SPH
|
USA | $1.64 Billion |
|
TRUSTPILOT GROUP LS -01
F:6VZ
|
Germany | €134.24 Million |
|
Xiamen King Long Motor Group Co Ltd
SHG:600686
|
China | CN¥23.55 Billion |
Liability Composition Analysis (2000–2023)
This chart breaks down Hubei Biocause Pharmaceutical's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Hubei Biocause Pharmaceutical balance sheet independence to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 11.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.87 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hubei Biocause Pharmaceutical's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hubei Biocause Pharmaceutical (2000–2023)
The table below shows the annual total liabilities of Hubei Biocause Pharmaceutical from 2000 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | CN¥268.30 Billion ≈ $39.26 Billion |
+5.63% |
| 2022-12-31 | CN¥254.00 Billion ≈ $37.17 Billion |
+12.17% |
| 2021-12-31 | CN¥226.43 Billion ≈ $33.13 Billion |
+10.55% |
| 2020-12-31 | CN¥204.81 Billion ≈ $29.97 Billion |
+19.83% |
| 2019-12-31 | CN¥170.92 Billion ≈ $25.01 Billion |
+12.27% |
| 2018-12-31 | CN¥152.24 Billion ≈ $22.28 Billion |
+33.88% |
| 2017-12-31 | CN¥113.71 Billion ≈ $16.64 Billion |
+16.65% |
| 2016-12-31 | CN¥97.48 Billion ≈ $14.26 Billion |
+15484.25% |
| 2015-12-31 | CN¥625.50 Million ≈ $91.53 Million |
+1.09% |
| 2014-12-31 | CN¥618.76 Million ≈ $90.54 Million |
-14.15% |
| 2013-12-31 | CN¥720.71 Million ≈ $105.46 Million |
+36.66% |
| 2012-12-31 | CN¥527.37 Million ≈ $77.17 Million |
+12.33% |
| 2011-12-31 | CN¥469.47 Million ≈ $68.70 Million |
+25.44% |
| 2010-12-31 | CN¥374.25 Million ≈ $54.76 Million |
-35.62% |
| 2009-12-31 | CN¥581.29 Million ≈ $85.06 Million |
+24.54% |
| 2008-12-31 | CN¥466.75 Million ≈ $68.30 Million |
+1.80% |
| 2007-12-31 | CN¥458.52 Million ≈ $67.10 Million |
+3.35% |
| 2006-12-31 | CN¥443.66 Million ≈ $64.92 Million |
+24.38% |
| 2005-12-31 | CN¥356.70 Million ≈ $52.20 Million |
-0.20% |
| 2004-12-31 | CN¥357.41 Million ≈ $52.30 Million |
-3.98% |
| 2003-12-31 | CN¥372.22 Million ≈ $54.47 Million |
+15.46% |
| 2002-12-31 | CN¥322.39 Million ≈ $47.18 Million |
+42.59% |
| 2001-12-31 | CN¥226.09 Million ≈ $33.08 Million |
-22.52% |
| 2000-12-31 | CN¥291.81 Million ≈ $42.70 Million |
-- |
About Hubei Biocause Pharmaceutical
Hubei Biocause Pharmaceutical Co., Ltd. primarily provides life and motor insurance products in China. It also engages in the pharmaceutical, chemical, and new energy fuel businesses. In addition, the company is involved in the contract research and production of APIs, intermediates, and formulations, including tablets, granules, capsules, etc.; and provision of chemicals comprising dimethyl ethe… Read more